Research progress in the treatment of type 2 diabetes mellitus with tirzepatide
Tirzepatide is a new-generation drug for diabetes mellitus,which was developed by Eli Lilly and Company and approved by the Food and Drug Administration(FDA)for marketing in May 2022.Tirzepatide has multiple pharmacological effects based on multiple target agonists compared to a single agonist and is a dual agonist of glucose-dependent insulinotropic peptides and glucagon-like peptide-1 receptors.The FDA approved the subcutaneous injection of the tirzepatide as a single therapy or combination therapy,combined with diet and physical exercise,to improve the blood glucose level of patients with diabetes mellitus.In addition to improving blood glucose control,tirzepatide can also effectively reduce body weight,improve cardiac metabolic parameters,improve blood pressure,reduce low-density lipoprotein,cholesterol,and triacylglycerol,etc.The effectiveness and safety of tirzepatide have been evaluated in Phases Ⅰ-Ⅴ clinical trials,and other clinical trials are currently underway to evaluate its application in other diseases.
万方数据
维普
